미국의 비알코올성 지방간염 바이오마커 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 최종 용도별, 부문별 예측(2024-2030년)

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The U.S. non-alcoholic steatohepatitis biomarkers market size is anticipated to reach USD 2.84 billion by 2030 and is anticipated to expand at a CAGR of 23.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of obesity, type 2 diabetes, and metabolic syndrome contribute to the growing incidence of non-alcoholic steatohepatitis (NASH) in the U.S. population, which is fueling the demand for biomarkers. According to the National Library of Medicine, Cirrhosis and chronic liver disease (CLD) are major worldwide health burdens leading to 1.1 million deaths yearly, and CLD ranks as the eleventh most common cause of death worldwide.

The market is experiencing significant innovation, primarily focused on developing novel biomarkers to accurately diagnose and monitor NASH, a liver disease caused by fat accumulation. These biomarkers are crucial for early detection, disease progression monitoring, and assessing treatment response in NASH patients. Companies and research institutions are actively developing these biomarkers to address the limitations of existing diagnostic tools and provide more accurate information about the disease status.

Digital health technologies such as mobile apps, wearable devices, and artificial intelligence (AI) algorithms are being used to develop novel biomarkers for NASH diagnosis and monitoring. The use of extensive clinical data sets and the latest advancements in AI applications have created a strong potential to increase diagnostic accuracy. In June 2023, the Kinetix Group's NASHNET network of excellence published a white paper that explored current perspectives and potential future applications of biomarkers for diagnosing and staging non-alcoholic fatty liver disease (NAFLD) and NASH.

U.S. Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

• Based on the type, the serum biomarkers segment dominated the market with a revenue share of 32.5% in 2023. The ability of serum biomarkers to provide valuable insights into disease progression and treatment response has made them indispensable tools for healthcare professionals
• The hepatic fibrosis biomarkers is expected to grow at the fastest rate during the forecast period due to the rising number of obesity, people following sedentary lifestyles, and metabolic syndromes
• The pharma & CRO industry in end-use segment dominated the market in 2023. This growth is attributable to the increasing healthcare expenditure and awareness in the U.S., particularly for chronic and complex diseases

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. End-use
  • 1.2.3. Region
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Volume price analysis (Model 2)
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type Outlook
  • 2.2.2. End-use Outlook
  • 2.2.3. Region Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: Type Estimates & Trend Analysis

• 4.1. Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by Type Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Serum biomarkers
    • 4.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.2. Hepatic fibrosis biomarkers
    • 4.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.3. Apoptosis biomarkers
    • 4.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.4. Oxidative stress biomarkers
    • 4.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: End-use Estimates & Trend Analysis

• 5.1. End-use Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by End-use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Pharma & CRO industry
    • 5.4.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.2. Hospitals
    • 5.4.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.3. Diagnostic labs
    • 5.4.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4.4. Academic Research Institutes
    • 5.4.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. U.S. Non-alcoholic Steatohepatitis Biomarkers Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2023 & 2030
• 6.2. U.S. Non-alcoholic Steatohepatitis Biomarkers Market by Region Outlook
• 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3.1. West
    • 6.3.1.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.2. Midwest
    • 6.3.2.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.3. Northeast
    • 6.3.3.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.4. Southwest
    • 6.3.4.1. Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.3.5. Southeast
    • 6.3.5.1. Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company heat map analysis, 2023
• 7.4. Company Profiles
  • 7.4.1. GENFIT
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Prometheus Laboratories
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Siemens Medical Solutions USA, Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Quest Diagnostics
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. AstraZeneca
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Laboratory Corporation of America Holdings
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Pfizer, Inc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Bristol-Myers Squibb Company
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives